Back to Awarded Treatment Trials


Awarded Trial: 02T-244

Grant ID

02T-244

Illness

Schizophrenia (first episode)

Primary Drug/Intervention

Minocycline

Primary Dosage

200 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Mendlovic

Sample Size

210

Duration of Study Period for Each Subject

24 weeks

Outcome Measurements

Cognitive battery, CGI, PANSS, SANS

Results

Minocycline is a second-generation tetracycline with anti-inflammatory and neuroprotective effects. It also counteracts the behavioral effects of NMDA receptor antagonists. Patients enrolled in the trial underwent a 2-week placebo lead-in and were then randomized to receive minocycline (n=36) or placebo (n=18) for 22 weeks. Fifty percent of patients receiving minocycline lost weight while 100% on placebo gained weight. Minocycline was associated with significant improvement in negative symptom, insight and global illness severity ratings. Minocycline use was also associated with significant improvement in working memory and other types of executive function.

Publication

N/A

Link

N/A

PI Name

Shlomo Mendlovic

Degree

MD

Center

N/A

Institution

Shalvata Mental Health Center

Address

Alyat Hanoar St

City or Town

Hod HaSaron

State or Province

N/A

Zip or Postal Code

45100

Country

Israel

Email Address

mendlovic@clalit.org.il